AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06599918
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of placebo on a variable dose depending on the participant's body weight. Administration is done orally, daily.
Trial: NCT06594640
Drug: Cyclophosphamide (CTX)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750mg/m2, D2
Trial: NCT06594640
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60mg/m2, D2-6
Trial: NCT06604065
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched non-caloric placebo. Study products will be in powder form and packaged in individual serving sizes and will be dissolved in 8 oz water for consumption.
Trial: NCT05083975
Drug: 1.8 ml of 4% articaine hydrochloride with epinephrine 1:100,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local dental anesthetic agent
Trial: NCT06004739
Drug: Start Antibiotics / Continue Antibiotics for treatment of bacteriuria
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be randomized to start or continue with antibiotics (with antibiotic duration determined by the Most Responsible Physician \[MRP\]). Antibiotics choice to be selected by the MRP.
Trial: NCT05116410
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administrated SC
Trial: NCT05387239
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline plus standard care
Trial: NCT01452698
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole placebo-matching capsules, orally, once daily for up to 8 weeks.~For participants whose EE is not endoscopically healed at Week 8, the participants will receive additional treatment of TAK-438 40 mg, tablets, orally, once daily for up to an additional 8 weeks.
Trial: NCT01452698
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-438 placebo-matching tablets, orally, once daily for up to 8 weeks.
Trial: NCT05577507
Drug: Calcium Carbonate 500 MG Oral Tablet
RxNorm normalized name: Calcium Carbonate 500 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: control group will administer standard therapy calcimate 500 mg three times daily within meals
Trial: NCT05122338
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Before the induction of anesthesia, normal saline is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
Trial: NCT06003972
Drug: guideline directed medical therapy (GDMT)
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GDMT for heart failure according to the AHA guidelines.
Trial: NCT03105843
Drug: Methacholine (MCh) Challenge Testing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visit 1: Informed consent, Baseline screening and pulmonary function tests and Low-dose methacholine challenge testing using partial and full flow-volume loops.
Trial: NCT05695378
Drug: KM-819
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive KM-819 400 mg orally daily.
Trial: NCT05695378
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive Placebo orally daily.
Trial: NCT01189032
Drug: Placebo ophthalmic solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02217826
Drug: DG3173
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05261126
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching enclitide chloride administered orally
Trial: NCT05295810
Drug: Sequential Gas Delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential Gas Delivery will be controlled using the RespirAct™ system (Thornhill Research Inc., Toronto, Canada)
Trial: NCT05340465
Drug: Low Molecular Weight Iron Dextran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infants in groups 2 and 3 will be given LMW-ID IV, 10 or 20 mg/kg/dose. They will be re-dosed if ferritin falls below 76. Iron parameters will be checked biweekly.
Trial: NCT05781906
Drug: HMPL-523
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D1-D7: HMPL-523 Tablet 300 mg QD
Trial: NCT05781906
Drug: 150 µCi [14C]HMPL-523
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D8: \[14C\] HMPL-523 Suspension 300 mg/150 μCi Single dose
Trial: NCT06262594
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug is administered
Trial: NCT04162756
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered per package insert
Trial: NCT05481151
Drug: P1101 (Ropeginterferon alfa-2b-njft)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropeginterferon alfa-2b-njft
Trial: NCT05494190
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750 mg/m2 po bid day 1-14
Trial: NCT06601114
Drug: Paracetamol Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: Paracetamol Group will receive Oral form of paracetamol with dosage of 15mg/kg every 6 hours for 3 days
Trial: NCT06601114
Drug: Ibuprofen group
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Group B: Ibuprofen Group will receive oral form of ibuprofen at initial dosage of 10mg/kg followed by 5mg/kg after 24 hours and 48 hours.
Trial: NCT05084118
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: continous application of isotone saline solution for 72 hours
Trial: NCT06308523
Drug: AP303 150 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AP303 Tablet 150 μg QD
Trial: NCT06308523
Drug: Placebo 150 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Tablet 150 μg QD
Trial: NCT06308523
Drug: AP303 300 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AP303 Tablet 300 μg QD
Trial: NCT06308523
Drug: Placebo 300 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Tablet 300 μg QD
Trial: NCT06724952
Drug: MTX S.C or IM and Silymarin 140 mg tab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM or S.C Methotrexate plus Silymarin tablets 140 mg once daily for 3 months.
Trial: NCT06724952
Drug: MTX S.C or IM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM or SC Methotrexate plus placebo tablet once daily for 3 months.
Trial: NCT06724653
Drug: RAS blocker tapering group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAS blocker tapering out
Trial: NCT05878561
Drug: Fimasartan + Indapamide
RxNorm normalized name: Indapamide
DrugBank: Indapamide (DB00808)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: a fixed dose combination
Trial: NCT05878561
Drug: Fimasartan + Indapamide placebo
RxNorm normalized name: Indapamide
DrugBank: Indapamide (DB00808)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: a fixed dose combination
Trial: NCT05929066
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT06315491
Drug: CBX-12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBX-12 is an alphalex construct which contains exatecan as the pharmacologically active moiety.
Trial: NCT06722729
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT06603857
Drug: Sham Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle serum regimen combined with laser treatment
Trial: NCT06590194
Drug: PH009-1 tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PH009-1 will be administered in fasting state
Trial: NCT05678881
Drug: placebo inhaled powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo inhaled powder
Trial: NCT06159608
Drug: Local heating + L-NAME (NG-nitro-L-arginine methyl ester; nitric oxide synthase inhibitor)
RxNorm normalized name: methyl L-arginine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Differences in endothelium- and nitric oxide (NO)-dependent dilation between groups
Trial: NCT05165771
Drug: Placebo to match GS-5718
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally
Trial: NCT05372991
Drug: CBT-009
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a Two-Stage Phase 1/2 study to evaluate the safety, tolerability and pharmacodynamics of CBT-009 eye drop in healthy volunteers.
Trial: NCT05372991
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a Two-Stage Phase 1/2 study to evaluate the safety, tolerability and pharmacodynamics of CBT-009 eye drop in healthy volunteers.
Trial: NCT06393504
Drug: Non-orexin receptor antagonist insomnia medication
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-orexin receptor antagonist insomnia medication received during or shortly prior to pregnancy.
Trial: NCT05141110
Drug: NVP-1705-R
RxNorm normalized name: R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NVP-1705-R
Trial: NCT06380491
Drug: Melatonin 3 MG Oral Tablet
RxNorm normalized name: melatonin 3 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants with OSA and nocturnal non-dipping Blood Pressure will be randomly assigned to a treatment with melatonin 3mg/d or to receive only the usual care.
Trial: NCT06322628
Drug: VSA006
FDA approved: no
EMA approved: no
PMDA approved: no
Description: every 12 weeks, subcutaneous injections
Trial: NCT06322628
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: every 12 weeks, subcutaneous injections
Trial: NCT05431673
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline 100mg/day for 6 weeks used as single or combination treatment for Rhinoscleroma
Trial: NCT00002110
Drug: Cysteamine
RxNorm normalized name: Cysteamine
DrugBank: Cysteamine (DB00847)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05804669
Drug: CRN04894
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRN04894 is an orally active investigational agent which antagonizes the action of ACTH at its receptor administered as oral tablets.
Trial: NCT06447870
Drug: biologic therapy(eg:IFX,ADA,UST,VDZ)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients received biologic therapy during the baseline period, and the specific type of medication was determined based on the professional doctor's diagnosis and treatment opinions. Patients were then divided into two groups based on whether primary non-response occurred or not.
Trial: NCT06243536
Drug: standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients not assigned to receive semaglutide will receive standard of care.
Trial: NCT05794204
Drug: RMP-A03 - Dose 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will randomized to low dose of RMP-A03
Trial: NCT05794204
Drug: RMP-A03 - Dose 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomized to high dose of RMP-A03
Trial: NCT05794204
Drug: RMP-A03 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomized to RMP-A03 Placebo
Trial: NCT06061926
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules (calcined magnesia) twice times at day, one capsule before breakfast and one capsule before dinner during 12 weeks. Homologated to the other intervention. Oral administration.
Trial: NCT04311099
Drug: Active drug
RxNorm normalized name: Capillary active drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of Ropivacaine
Trial: NCT04311099
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of Saline solution
Trial: NCT04792645
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pill that contains no medicine
Trial: NCT06176222
Drug: PRECEDEX INJ★ 2ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patient received PRECEDEX INJ★ 2ML 0.1\~0.4 mcg/kg/hr intravenous infusion 12 hours after the surgery immediately
Trial: NCT06655259
Drug: Standard Medical Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Standard Medical Therapy, which includes ADT, typically with an LHRH agonist or antagonist, to reduce testosterone levels, a key driver of prostate cancer progression. In addition to ADT, participants may be treated with second-generation anti-androgen drugs such as Abiraterone or Enzalutamide. These medications block androgen receptor signaling and further inhibit the cancer\&#39;s ability to grow.
Trial: NCT05074290
Drug: Epidiferphane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the phase I portion of the study, subjects will be assigned to take either two (half target dose) or four (full target dose) Epidiferphane tablets orally three times daily following a 3 + 3 design. Three subjects will be sequentially enrolled at each of the 2 dose levels (beginning with the half target dose) until at least one dose-limiting toxicity (DLT) occurs. Dosing escalation will be stopped if two or more DLTs occur at either dose level. The maximum tolerated dose will be one dose level lower than the dose level at which 2 or more DLTs occur. Dose escalation will occur separately for each taxane regimen (docetaxel or paclitaxel).~All subjects in the phase II portion of the study will receive the maximum tolerated dose determined in the phase I portion of the study for their taxane regimen.~Subjects in both portions of the study will receive treatment with Epidiferphane for a maximum of three months.
Trial: NCT05074290
Drug: Taxane Chemotherapy
RxNorm normalized name: acetaminophen / oxycodone hydrochloride Oral Capsule [Taxadone]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects on both phases of the study will be concurrently treated with a taxane regimen containing either paclitaxel given weekly, nab-paclitaxel given weekly or every 3 weeks or docetaxel given every 3 weeks. The choice of taxane regimen will be determined by the treating physician prior to consenting to participate in this trial.
Trial: NCT04691570
Drug: ANX005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANX005 is provided as a solution for IV infusion
Trial: NCT05584007
Drug: Placebo Only Product in Oral Dose Form
RxNorm normalized name: placebo Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be prescribed flucloxacillin 500mg QDS for 5 days followed by a blinded placebo for 2 days, reaching a total of 5 days of antibiotic treatment
Trial: NCT05605366
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Minocycline is a second-generation tetracycline antibiotic with good central nervous system penetration and anti-neuroinflammatory effect.
Trial: NCT05605366
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is capsule that is identical in size and appearance as the drug, but without active drug ingredient.
Trial: NCT05180773
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo one tablet by mouth twice daily for 2 weeks then once daily for 6 weeks. Subjects who are not on anticoagulation will not receive rivaroxaban but will receive a second placebo once daily for 8 weeks while on study drug.
Trial: NCT05180773
Drug: Guideline Directed Medical Therapy for Heart Failure (GDMT)
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GDMT will potentially include angiotensin converting enzyme inhibitors (ACEi), angiotensin II receptor antagonists (ARB), angiotensin receptor blocker-neprilysin inhibitors (ARNI), beta adrenergic receptor antagonists (beta blockers) , Mineralocorticoid receptor antagonists (MRA), sodium-glucose cotransporter-2 inhibitors (SGLT2i),
Trial: NCT06595797
Drug: HRS9531
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRS9531
Trial: NCT06595797
Drug: HRS9531placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRS9531placebo
Trial: NCT06591845
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Substance: Placebo, Pharmaceutical Form: Suspension, Route of Administration: Oral
Trial: NCT06596161
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05978167
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo pill
Trial: NCT06073938
Drug: NHWD-870
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The base dosage administered is 2.0 mg/dose/day, and the frequency and dose of administration may be adjusted based on safety data.
Trial: NCT05796401
Drug: Personalized neuroprotective strategies : Vitamin B12, folinic acid, Omega 3, NAC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalised neuroprotective medication adapted to the individual's biological profile :~* Vitamin B12 : 500 micrograms per day~* Folinic acid : 50 mg per day~* Omega 3 : 1380 mg EicosaPentaenoic Acid (EPA) + 1140 mg DocosaHexaenoic Acid (DHA) per day~* N-acetyl-cysteine (NAC) : 2400 mg per day~duration of supplementation(s) : 12 weeks
Trial: NCT06585852
Drug: Xenograft
RxNorm normalized name: Xenograft heart
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scaffold material of choice
Trial: NCT05710367
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matched oral drug. Placebo tablet will have the same color, taste, smell and package as the verum tablet
Trial: NCT06587425
Drug: LM-302+Candonilimab+Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: LM-302: 1.8mg/kg ivgtt d1, q2w; Canonilimab: 6mg/kg ivgtt d1, q2w; Capecitabine: 1000mg/m\^2 po bid d1-10, q2w.
Trial: NCT05078047
Drug: Reduced dose intensity of IO
RxNorm normalized name: Io-Shield
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After 6 months of treatment with standard IO, IO will be administered every 3 months (at the same dose levels) until disease progression, unacceptable toxicity, death or patient's choice or investigator's decision
Trial: NCT06371092
Drug: UltraEZ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General examination with bite-wings. Dental prophylaxis (dental scaling and polishing with an abrasive paste). Alginate impressions of both arches. Creation of individualized bleaching trays and a position-finder tray of both arches. Application of the UltraEZ gel in the bleaching trays for 30 minutes. Application of the bleaching gel in the bleaching trays during 6-8 hours
Trial: NCT06371092
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General examination with bite-wings. Dental prophylaxis (dental scaling and polishing with an abrasive paste). Alginate impressions of both arches. Creation of individualized bleaching trays and a position-finder tray of both arches. Application of the placebo gel in the bleaching trays for 30 minutes. Application of the bleaching gel in the bleaching trays during 6-8 hours
Trial: NCT05642403
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched inhaled placebo
Trial: NCT05797467
Drug: FOLFOX chemotherapy regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy regimens recommended include oxaliplatin-based CapeOx or FOLFOX regimens, or single-agent 5-FU/LV, capecitabine, or combination with targeted therapy.
Trial: NCT04732221
Drug: MK-5475
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-5475 (soluble guanylate cyclase stimulator) 380 µg, 100 µg or 32 µg administered as dry powder inhalation
Trial: NCT04732221
Drug: Placebo to MK-5475
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered as dry powder inhalation
Trial: NCT06509880
Drug: FOLFOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (Day 1-2: Oxaliplatin 100 mg/m2 IV infusion, given as a 120 minutes IV infusion in 500 mL D5W, concurrent with leucovorin 400 mg/m2 (or levoleucovorin 200 mg/m2) IV infusion, followed by 5-FU 400 mg/m2 IV bolus, followed by 46-hour 5-FU infusion (2400 mg/m2 for first two cycles, and may be increased to 3000 mg/m2 if tolerated by patient (no toxicity \> grade 1 during the first two cycles), days 3-14: Rest days)
Trial: NCT05587933
Drug: Antispasmodic
RxNorm normalized name: Antispasmodic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antispasmodic
Trial: NCT05843643
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablet
Trial: NCT04682366
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral drug: 10 days of identical-appearing placebo
Trial: NCT04098718
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30mg tablet daily for 5 days
Trial: NCT05477823
Drug: Androgen deprivation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care ADT
Trial: NCT06516978
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
Trial: NCT06516978
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
Trial: NCT06775860
Drug: ICP-332 Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICP-332 will be administered as tablet